Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free VRPX Stock Alerts

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
Compare

VRPX vs. SXTPW, BFRIW, CALA, CINGW, and CLVR

Should you buy Virpax Pharmaceuticals stock or one of its competitors? Virpax Pharmaceuticals's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Clever Leaves (CLVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Virpax Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Virpax Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Virpax Pharmaceuticals' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Virpax Pharmaceuticals Neutral

60 Degrees Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

60 Degrees Pharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Summary

60 Degrees Pharmaceuticals beats Virpax Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Biofrontera?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Biofrontera has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Biofrontera$46.18MN/AN/AN/AN/A

Biofrontera's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Biofrontera N/A N/A N/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Biofrontera had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Virpax Pharmaceuticals. Biofrontera's average media sentiment score of 1.87 beat Virpax Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Biofrontera Very Positive

Summary

Biofrontera beats Virpax Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Calithera Biosciences?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Calithera Biosciences had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Calithera Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Calithera Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Calithera Biosciences N/A N/A N/A

Virpax Pharmaceuticals has a beta of -16.07, indicating that its stock price is 1,707% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Calithera Biosciences beats Virpax Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Cingulate?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

In the previous week, Cingulate had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Virpax Pharmaceuticals. Cingulate's average media sentiment score of 0.44 beat Virpax Pharmaceuticals' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Cingulate Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
CingulateN/AN/AN/AN/AN/A

Cingulate's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Cingulate N/A N/A N/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cingulate beats Virpax Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Virpax Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Virpax Pharmaceuticals Neutral

Clever Leaves has a beta of 3845.97, indicating that its share price is 384,497% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.07, indicating that its share price is 1,707% less volatile than the broader market.

Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Summary

Clever Leaves beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

Export
MetricVirpax PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.15B$7.20B$12.90B
Dividend YieldN/A2.62%2.54%11.28%
P/E Ratio0.00787.65273.1625.45
Price / SalesN/A792.41592.5973.08
Price / CashN/A91.9576.7453.00
Price / BookN/A11.9712.986.14
Net Income-$15.19M$2.83B$3.48B$348.86M

Virpax Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$0.00N/AN/A7
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-58.7%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.03
+13.1%		N/A-81.6%$0.00$46.18MN/A70
CALA
Calithera Biosciences
N/AN/AN/A+50.0%$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
+44.3%		N/A-87.6%$0.00N/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Look at this $5 stock’s address
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...
Freedom Financial | Sponsoredtc pixel